Market
What will be Pfizer's gross leverage position by the end of 2025?
3
Resolution / Starting Odds
Below 3.0x • 25%
3.0x - 3.25x • 25%
3.26x - 3.5x • 25%
Above 3.5x • 25%
Pfizer's official financial statements or disclosures
Story
Pfizer Projects 2025 Revenue of $61B-$64B, Adjusted EPS of $2.80-$3.00, Stock Rises 3%
Dec 17, 2024, 12:06 PM
Pfizer Inc. ($PFE) has provided its full-year guidance for 2025, projecting revenues between $61 billion and $64 billion, which aligns closely with Wall Street expectations of $63.23 billion. The company also anticipates adjusted diluted earnings per share (EPS) in the range of $2.80 to $3.00, slightly below the expected $2.90. Pfizer's guidance reflects an operational growth of 10% to 18% from the midpoint of its 2024 estimates. Additionally, the company plans to implement a manufacturing optimization program aimed at achieving $500 million in cost savings in 2025, building on an earlier $4 billion cost realignment strategy. The stock rose more than 3% in pre-market trading following the announcement, as the company seeks to address criticism regarding its turnaround strategy from activist hedge fund Starboard Value. Pfizer's gross leverage position is targeted at 3.25x, down from approximately 3.5x in the last quarter.
View original story
Similar markets
Revenue decrease over 10% • 25%
Profit decrease over 10% • 25%
Profit increase over 10% • 25%
Revenue increase over 10% • 25%
Debt restructuring • 25%
Maintain current debt levels • 25%
Reduce debt significantly • 25%
Increase debt levels • 25%
Other outcome • 25%
Successful restructuring • 25%
Partial restructuring • 25%
Failure to restructure • 25%
Below $1.40 • 25%
$1.40 to $1.60 • 25%
$1.61 to $1.80 • 25%
Above $1.80 • 25%
Increase by more than 20% • 25%
Increase by 10% to 20% • 25%
Decrease by more than 10% • 25%
Remain within ±10% • 25%
5% to 10% • 25%
11% to 15% • 25%
More than 15% • 25%
Less than 5% • 25%
Stock price increases by 10% to 15% • 25%
Stock price increases by more than 15% • 25%
Stock price increases by 5% to 10% • 25%
Stock price increases by less than 5% • 25%
No change • 25%
Downgrade • 25%
Upgrade • 25%
Not rated • 25%
Revenue increases by <5% • 25%
Revenue decreases • 25%
Revenue increases by >10% • 25%
Revenue increases by 5-10% • 25%
